Aljuffali IA[Author] - Search Results

Year	Number of Results
2011	3
2012	3
2013	8
2014	17
2015	19
2016	12
2017	9
2018	2
2019	1
2020	4
2021	0

1

Current pathogenic Escherichia coli foodborne outbreak cases and therapy development.

Yang SC, Lin CH, Aljuffali IA, Fang JY. Yang SC, et al. Among authors: aljuffali ia. Arch Microbiol. 2017 Aug;199(6):811-825. doi: 10.1007/s00203-017-1393-y. Epub 2017 Jun 9. Arch Microbiol. 2017. PMID: 28597303 Review.

2

Injectable Drug-Loaded Nanocarriers for Lung Cancer Treatments.

Yu HP, Aljuffali IA, Fang JY. Yu HP, et al. Among authors: aljuffali ia. Curr Pharm Des. 2017;23(3):481-494. doi: 10.2174/1381612822666161027113654. Curr Pharm Des. 2017. PMID: 28292243 Review.

3

Nanomedical strategies for targeting skin microbiomes.

Aljuffali IA, Huang CH, Fang JY. Aljuffali IA, et al. Curr Drug Metab. 2015;16(4):255-71. doi: 10.2174/1389200216666150812124923. Curr Drug Metab. 2015. PMID: 26264194 Review.

4

Pharmaceutical companies' views on a health technology assessment (HTA) entity in Saudi Arabia.

Al-Omar HA, Attuwaijri AA, Aljuffali IA. Al-Omar HA, et al. Among authors: aljuffali ia. Saudi Pharm J. 2020 Jun;28(6):662-668. doi: 10.1016/j.jsps.2020.04.006. Epub 2020 Apr 23. Saudi Pharm J. 2020. PMID: 32550796 Free PMC article.

5

Exploring the status and views of managed entry agreements in Saudi Arabia: mixed-methods approach.

Al-Omar HA, Alghannam HH, Aljuffali IA. Al-Omar HA, et al. Among authors: aljuffali ia. Expert Rev Pharmacoecon Outcomes Res. 2020 Jul 13:1-9. doi: 10.1080/14737167.2020.1792295. Online ahead of print. Expert Rev Pharmacoecon Outcomes Res. 2020. PMID: 32658625

6

The codrug approach for facilitating drug delivery and bioactivity.

Aljuffali IA, Lin CF, Chen CH, Fang JY. Aljuffali IA, et al. Expert Opin Drug Deliv. 2016 Sep;13(9):1311-25. doi: 10.1080/17425247.2016.1187598. Epub 2016 May 27. Expert Opin Drug Deliv. 2016. PMID: 27159251 Review.

7

What local experts expect from a health technology assessment (HTA) entity in Saudi Arabia: workshop conclusions.

Al-Omar HA, Attuwaijri AA, Aljuffali IA. Al-Omar HA, et al. Among authors: aljuffali ia. Expert Rev Pharmacoecon Outcomes Res. 2020 Feb;20(1):99-104. doi: 10.1080/14737167.2019.1610398. Epub 2019 Apr 29. Expert Rev Pharmacoecon Outcomes Res. 2020. PMID: 31032687

8

Cutaneous delivery of natural antioxidants: the enhancement approaches.

Aljuffali IA, Hsu CY, Lin YK, Fang JY. Aljuffali IA, et al. Curr Pharm Des. 2015;21(20):2745-57. doi: 10.2174/1381612821666150428125428. Curr Pharm Des. 2015. PMID: 25925121 Review.

9

Empirical Monetary Valuation of a Quality-Adjusted Life-Year in the Kingdom of Saudi Arabia: A Willingness-to-Pay Analysis.

Bazarbashi S, De Vol EB, Maraiki F, Al-Jedai A, Ali AA, Alhammad AM, Aljuffali IA, Iskedjian M. Bazarbashi S, et al. Among authors: aljuffali ia. Pharmacoecon Open. 2020 Dec;4(4):625-633. doi: 10.1007/s41669-020-00211-0. Pharmacoecon Open. 2020. PMID: 32291726 Free PMC article.

10

Delivery and targeting of nanoparticles into hair follicles.

Fang CL, Aljuffali IA, Li YC, Fang JY. Fang CL, et al. Among authors: aljuffali ia. Ther Deliv. 2014;5(9):991-1006. doi: 10.4155/tde.14.61. Ther Deliv. 2014. PMID: 25375342 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results